Immune responses elicited by rMV-SLAMblind oncolytic therapy exert a synergistic effect on cancer therapy
Oncolytic virotherapy has emerged as a promising strategy for cancer therapy. rMV-SLAMblind is a recombinant measles virus that lacks the ability to interact with SLAM and specifically infects and lyses NECTIN4 + cancer cells. We previously reported that rMV-SLAMblind oncolytic virotherapy (rMV-OVT) exerts anti-t...